Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation

Saturday, 28 December, 2013
  • A. Nicholas R. Barnett ,
  • Miriam Manook,
  • Myura Nagendran,
  • Shivakumar Kenchayikoppad,
  • Anthony Dorling,
  • Vassilis G. Hadjianastassiou,
  • Nizam Mamode

Abstract

ABO blood group incompatible renal transplantation, using desensitization procedures, is an effective strategy. Efforts have been made to reduce desensitization: these are usually applied to all patients indiscriminately. The Guy's Hospital ABO blood group incompatible desensitization regimen uses a tiered approach, tailoring strategy according to initial antibody titres. Sixty-two ABO blood group incompatible living donor transplant recipients were compared with 167 recipients of blood group compatible living donor renal transplants. There were no statistically significant differences in allograft survival rates at 1 or 3 years post-transplant, rejection in the first year post-transplant or renal function in the first 3 years post-transplant. There was a higher rate of death in ABO blood group incompatible transplant recipients - this could be associated with differences in age and HLA mismatch between the two groups. Four ABO blood group incompatible patients experienced antibody-mediated rejection (no episode was associated with a rise in ABO blood group antibodies). Of the patients who received no desensitization, or rituximab alone, none has experienced antibody mediated rejection or experienced allograft loss. Tailoring the use of desensitization in ABO blood group incompatible renal transplantation according to initial ABO blood group antibody titres led to comparable results to blood group compatible transplantation.

Where can I read this paper?

Full article on Wiley On Library. Note: you will need the credentials or your institution to login or you can purchase access.

Published: 2014 Feb;27(2):187-96. doi: 10.1111/tri.12234. Epub 2013 Dec 28.